MedPath

Myoview

These highlights do not include all the information needed to use MYOVIEW safely and effectively. See full prescribing information for MYOVIEW. MYOVIEW (Kit for the preparation of technetium Tc99m tetrofosmin injection) for intravenous use Initial U.S. Approval: 1996

Approved
Approval ID

4a8e5ed7-57f4-4d48-93cd-5f307207a3a0

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 10, 2024

Manufacturers
FDA

Medi-Physics Inc. dba GE Healthcare

DUNS: 095263729

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tetrofosmin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code17156-024
Application NumberNDA020372
Product Classification
M
Marketing Category
C73594
G
Generic Name
Tetrofosmin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 12, 2022
FDA Product Classification

INGREDIENTS (4)

Stannous ChlorideInactive
Quantity: 0.03 mg in 1 1
Code: 1BQV3749L5
Classification: IACT
Disodium SulfosalicylateInactive
Quantity: 0.32 mg in 1 1
Code: WFP6MAA96R
Classification: IACT
TetrofosminActive
Quantity: 0.23 mg in 1 1
Code: 3J0KPB596Q
Classification: ACTIB
Sodium BicarbonateInactive
Quantity: 1.8 mg in 1 1
Code: 8MDF5V39QO
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Myoview - FDA Drug Approval Details